In a thalassemia patient with anemia and elevated ferritin, what is the likely cause and appropriate management?

Elevated Ferritin with Anemia in Thalassemia

In thalassemia patients presenting with anemia and elevated ferritin, the elevated ferritin reflects iron overload from chronic hemolysis, increased intestinal iron absorption driven by ineffective erythropoiesis, and transfusions (if applicable), requiring iron chelation therapy rather than iron supplementation. 1, 2

Pathophysiology of Iron Overload in Thalassemia

The combination of anemia with elevated ferritin in thalassemia is paradoxical but expected:

• Ineffective erythropoiesis drives inappropriately increased intestinal iron absorption despite existing iron overload, creating a vicious cycle 2
• Chronic hemolysis releases iron from destroyed red blood cells, exceeding the body's capacity to safely store it 2
• Transfusional iron loading (in transfusion-dependent patients) adds approximately 200-250 mg of iron per unit of packed RBCs 3
• The anemia persists because the underlying genetic defect prevents normal hemoglobin production, regardless of iron availability 1

Diagnostic Thresholds for Iron Toxicity

Monitor for these critical values indicating dangerous iron overload 2:

• Serum ferritin >2,500 ng/mL indicates high risk for organ damage
• Liver iron concentration >440 μmoles/g dry weight
• Transferrin saturation >75% leads to non-transferrin-bound iron (NTBI) emergence
• Cardiac T2 <20 ms* on MRI indicates cardiac iron deposition 4

Management Algorithm

For Transfusion-Dependent Thalassemia Major

Initiate iron chelation therapy when ferritin levels indicate iron overload, typically starting in early childhood after 10-20 transfusions 3:

• Deferasirox (oral) or deferiprone (oral) are preferred due to superior compliance compared to subcutaneous deferoxamine 3
• Target ferritin levels should not exceed 500 mg/L to avoid toxicity, especially in children and adolescents 5
• Combination therapy with subcutaneous deferoxamine plus oral deferiprone may be used for patients with impaired cardiac function 4

For Non-Transfusion-Dependent Thalassemia Intermedia

• Iron chelation is indicated from age 5 years onward to prevent progressive iron accumulation 6
• Even without transfusions, these patients develop positive iron balance and require chelation therapy tailored to individual ferritin levels 6
• Splenectomized patients show significantly higher ferritin levels and require more aggressive chelation 7

Cardiac Monitoring and Urgent Intervention

Cardiac T2 assessment is critical* for risk stratification 4:

• T2 <6 ms*: 47% risk of heart failure within 1 year; treat as aggressively as overt heart failure 4
• T2 6-10 ms*: Intensified chelation therapy required 4
• T2 10-20 ms*: Moderate chelation with dose adjustments 4
• For acute heart failure, consider 24-hour continuous intravenous deferoxamine with careful monitoring 4

Critical Pitfalls to Avoid

Never administer iron supplementation based solely on anemia in thalassemia patients—this is a common and dangerous error 1:

• The microcytic anemia with normal or elevated ferritin should immediately suggest thalassemia rather than iron deficiency 1
• Hemoglobin electrophoresis, not empiric iron therapy, is the appropriate next step 1
• While iron deficiency can occasionally coexist in thalassemia carriers (16% prevalence), this requires specific documentation with serum iron studies before supplementation 8

Monitor for chelator-mediated toxicity during aggressive iron removal 4:

• Adjust chelation according to liver iron and ferritin trends to prevent over-chelation
• Cardiac iron removes very slowly (over years), requiring sustained long-term therapy 4
• In patients developing anemia during phlebotomy despite elevated ferritin (as in ferroportin disease), extend phlebotomy intervals 5

Long-Term Outcomes

Effective iron chelation prevents and reverses the major complications of iron overload 2:

• Cirrhosis, cardiomyopathy, and endocrine disorders are largely preventable with proper chelation
• Life expectancy has improved dramatically over the past 50 years with availability of transfusions and chelation therapy 1
• Compliance with chelation is essential for long-term survival, particularly after episodes of cardiac decompensation 4